Pluristem stem cell trial to treat muscle injury meets main goal

January 22, 2014

Pluristem Therapeutics Inc said results from its early/mid-stage clinical trial indicated its placenta-derived stem cells for the treatment of muscle injury were safe and provided evidence the cells might be effective in treating orthopedic injuries. “Patients treated with PLX-PAD had a greater improved change of maximal voluntary muscle contraction force than the placebo group,” Israel-based Pluristem said in a statement on Tuesday. (Reuters)